AGMB Insider Trading Activity and SEC Form 4 Filings
AGMB insider trading summary
Over the past 12 months, insiders at AgomAb Therapeutics NV (AGMB) reported 12 open-market purchases worth $459K by 3 insiders and no sales on SEC Form 4. Net insider buying was $459K.
Latest AGMB insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 5, 2026 | David R Epstein | Director | Buy | $34K (5,000 @ $6.81) |
| Nov 5, 2026 | David R Epstein | Director | Buy | $35K (5,000 @ $6.91) |
| Nov 5, 2026 | David R Epstein | Director | Buy | $35K (5,000 @ $6.98) |
| Oct 21, 2026 | David R Epstein | Director | Buy | $45K (5,000 @ $8.90) |
| Oct 21, 2026 | David R Epstein | Director | Buy | $44K (5,000 @ $8.86) |
| Oct 6, 2026 | Pierre Thadee Victor Kemula | Chief Financial Officer | Buy | $43K (5,000 @ $8.57) |
| Oct 6, 2026 | Tim Jasper Knotnerus | Chief Executive Officer | Buy | $44K (5,000 @ $8.70) |
| Oct 6, 2026 | Pierre Thadee Victor Kemula | Chief Financial Officer | Buy | $17K (2,000 @ $8.54) |
| Oct 6, 2026 | Pierre Thadee Victor Kemula | Chief Financial Officer | Buy | $26K (3,000 @ $8.67) |
| Oct 6, 2026 | David R Epstein | Director | Buy | $44K (5,000 @ $8.70) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.